Detrol LA Related Published Studies
Well-designed clinical trials related to Detrol LA (Tolterodine)
Effects of terazosin and tolterodine on ureteral stent related symptoms: a
double-blind placebo-controlled randomized clinical trial. [2013]
Efficacy of tolterodine for medical treatment of intramural ureteral stone with vesical irritability. [2011.06]
Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. [2011.05]
[Tolterodine tartrate combined with alpha-receptor blocker for benign prostatic hyperplasia with detrusor overactivity]. [2011.04]
The efficacy of additive tolterodine extended release for 1-year in older men with storage symptoms and clinical benign proastatic hyperplasia. [2011.04]
[Comparisons of efficacy and safety of tolterodine and oxybutynin in children with idiopathic overactive bladder]. [2011.01]
Investigation of the clinical efficacy and safety of pregabalin alone or combined with tolterodine in female subjects with idiopathic overactive bladder. [2011.01]
Electrical stimulation compared with tolterodine for treatment of urge/urge incontinence amongst women--a randomized controlled trial. [2010.12]
Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an alpha-blocker: effect of baseline prostate-specific antigen concentration. [2010.11]
Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms. [2010.10]
The effect of tolterodine 4 and 8 mg on the heart rate variability in healthy subjects. [2010.10]
Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. [2010.09.21]
[Combination of tamsulosin and tolterodine alleviates refractory lower urinary tract symptoms in male patients]. [2010.09]
Electrical stimulation compared with tolterodine for treatment of urge/urge incontinence amongst women-a randomized controlled trial. [2010.06.29]
Proof of principle: The effect of antimuscarinics on bladder filling sensations in healthy subjects--a placebo controlled double blind investigation using 4 and 8 mg tolterodine extended release. [2010.03]
Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. [2010.01]
Comparison of fesoterodine and tolterodine extended release for the treatment of
overactive bladder: a head-to-head placebo-controlled trial. [2010]
The effects of tolterodine extended release and alfuzosin for the treatment of double-j stent-related symptoms. [2009.11]
Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. [2009.09]
Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence. [2009.09]
Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers. [2009.09]
[Combination of tolterodine and tamsulosin for benign prostatic hyperplasia] [2009.07]
Continued symptom improvement in sexually active women with overactive bladder and urgency urinary incontinence treated with tolterodine ER for 6 months. [2009.04]
The pharmacokinetic profile of fesoterodine: similarities and differences to tolterodine. [2009.03.07]
Continued symptom improvement in sexually active women with overactive bladder and urgency urinary incontinence treated with tolterodine ER for 6 months. [2009.01.09]
Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome. [2009]
Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. [2008.11]
Comparison of fesoterodine and tolterodine in patients with overactive bladder. [2008.11]
Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. [2008.11]
Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder. [2008.09]
Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. [2008.09]
Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine. [2008.06]
Does tolterodine extended release affect the bladder electrical perception threshold? A placebo controlled, double-blind study with 4 and 8 mg in healthy volunteers. [2007.12]
Long-term tolerability of tolterodine extended release in children 5-11 years of age: results from a 12-month, open-label study. [2007.11]
Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder. [2007.04]
Thorough QT study with recommended and supratherapeutic doses of tolterodine. [2007.03]
Effects of bladder training and/or tolterodine in female patients with overactive bladder syndrome: a prospective, randomized study. [2006.12]
Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. [2006.11.15]
Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder. [2006.09]
Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. [2006.08]
Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia. [2006.06]
Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. [2006.05]
Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. [2006.04]
Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. [2006.03]
Comparison of efficacy of oxybutynin and tolterodine for prevention of catheter related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study. [2006.03]
Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability. [2006.02]
Evaluating the efficacy of the valsalva maneuver on venous cannulation pain: a prospective, randomized study. [2005.10]
High performance liquid chromatography-electrospray ionization mass spectrometric determination of tolterodine tartrate in human plasma. [2005.09.25]
A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. [2005.09]
Propiverine versus tolterodine: efficacy and tolerability in patients with overactive bladder. [2005.09]
Effect of the proton pump inhibitor omeprazole on the pharmacokinetics of extended-release formulations of oxybutynin and tolterodine. [2005.08]
Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients. [2005.05]
Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial. [2005.05]
Tolterodine treatment for children with symptoms of urinary urge incontinence suggestive of detrusor overactivity: results from 2 randomized, placebo controlled trials. [2005.04]
Comparison of dry mouth in women treated with extended-release formulations of oxybutynin or tolterodine for overactive bladder. [2005]
Well-designed clinical trials possibly related to Detrol LA (Tolterodine)
Phase II study on the efficacy and safety of the EP1 receptor antagonist ONO-8539
for nonneurogenic overactive bladder syndrome. [2014]
Trastuzumab: a review of its use in HER2-positive advanced gastric cancer. [2013]
Evaluation of anti-hyperalgesic and analgesic effects of two benzodiazepines in
human experimental pain: a randomized placebo-controlled study. [2013]
Which anticholinergic drug for overactive bladder symptoms in adults. [2012]
Initial combined treatment with anticholinergics and alpha-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. [2011.12]
Systematic review and meta-analysis: do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events? [2011.07]
Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: a decision-tree model. [2011.05.20]
Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder. [2011.05]
Long-term safety, tolerability, and efficacy of fesoterodine treatment in men and women with overactive bladder symptoms. [2011.05]
Correlates and predictors of patient satisfaction with drug therapy and combined drug therapy and behavioral training for urgency urinary incontinence in women. [2011.03]
[Clinical effectiveness and safety of combined therapy with an alpha-blocker and an anticholinergic drug for patients with benign prostatic hyperplasia]. [2010.12.01]
The outcome of adding peripheral neuromodulation (Stoller afferent neuro-stimulation) to anti-muscarinic therapy in women with severe overactive bladder. [2010.10]
A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder. [2010.08]
Comparison of selective M3 and nonselective muscarinic receptor antagonists on gastrointestinal transit and bowel habits in humans. [2010.07]
The effects of drug and behavior therapy on urgency and voiding frequency. [2010.06]
Effect of fluid management on fluid intake and urge incontinence in a trial for overactive bladder in women. [2010.06]
The effects of drug and behavior therapy on urgency and voiding frequency. [2010.06]
Central nervous system findings on functional magnetic resonance imaging in patients before and after treatment with anticholinergic medication. [2010.05]
The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime dosing. [2010.02]
Long-term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder. [2010.01]
Canadian cost-effectiveness analysis of solifenacin compared to oxybutynin immediate-release in patients with overactive bladder. [2010]
[Follow-up at 24 months after treatment of overactive bladder with 0.2 % sodium chondroitin sulfate] [2009.11]
Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine. [2009.09]
Efficacy and tolerability of fesoterodine in women with overactive bladder. [2009.07]
A multicomponent behavioural and drug intervention for nocturia in elderly men: rationale and pilot results. [2009.07]
Influence of food on the pharmacokinetic profile of fesoterodine. [2009.06]
Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study. [2009.04]
Multinational clinical trial in Japan and Korea on detrusitol. [2009.02]
Pharmacokinetic profile of fesoterodine. [2008.11]
Combination therapy with desmopressin and an anticholinergic medication for nonresponders to desmopressin for monosymptomatic nocturnal enuresis: a randomized, double-blind, placebo-controlled trial. [2008.11]
Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy. [2008.11]
Impact of fesoterodine on quality of life: pooled data from two randomized trials. [2008.07]
Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. [2008.05]
A simple validated scale to measure urgency. [2008.03]
The effects of anticholinergic drugs on attention span and short-term memory skills in children. [2008]
The effects of anticholinergic drugs on attention span and short-term memory skills in children. [2007.09.07]
Age related pathogenesis of nocturia in patients with overactive bladder. [2007.08]
[Clinical effectiveness and safety study of combined therapy with an alpha-blocker and an anticholinergic for patients with LUT/BPH] [2007.06.19]
Efficacy of combined anticholinergic treatment and behavioral modification as a first line treatment for nonneurogenic and nonanatomical voiding dysfunction in children: a randomized controlled trial. [2007.06]
Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study. [2007.03.05]
Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration. [2007.02]
The responsiveness of the OAB-q among OAB patient subgroups. [2007]
Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration. [2006.11.28]
The validation of patient-rated global assessments of treatment benefit, satisfaction, and willingness to continue--the BSW. [2005.11]
Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. [2005.09]
Trospium chloride for the treatment of overactive bladder with urge incontinence. [2005.05]
|
